Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Receivables for 10 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 29.11% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, up 29.11%, and an annual FY2024 reading of $3.9 million, up 51.56% over the prior year.
  • Receivables was $4.2 million for Q3 2025 at Sunshine Biopharma, up from $3.6 million in the prior quarter.
  • Across five years, Receivables topped out at $4.2 million in Q3 2025 and bottomed at $22.0 in Q3 2022.
  • Average Receivables over 5 years is $2.1 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Receivables plummeted 98.05% in 2022, then surged 9245895.45% in 2023.
  • Year by year, Receivables stood at $7798.0 in 2021, then surged by 24421.07% to $1.9 million in 2022, then soared by 33.48% to $2.6 million in 2023, then surged by 51.56% to $3.9 million in 2024, then grew by 7.42% to $4.2 million in 2025.
  • Business Quant data shows Receivables for SBFM at $4.2 million in Q3 2025, $3.6 million in Q2 2025, and $3.4 million in Q1 2025.